Table 1 Cohort characteristics
Characteristic | All subjects (n = 615) |
|---|---|
Age, years | 67 (50, 81) |
Female | 188 (30.6%) |
African American | 26 (4.2%) |
Body mass index, kg/m2 | 27.7 (22.5, 36.9) |
Medical history | |
Hypertension | 544 (88.5%) |
Congestive heart failure | 243 (39.5%) |
Left ventricular ejection fraction, % | 60 (35, 60) |
Myocardial infarction | 110 (17.9%) |
Prior cardiac surgery | 110 (17.9%) |
Diabetes | 202 (32.8%) |
Current smoking | 88 (14.3%) |
Chronic obstructive pulmonary disease | 64 (10.4%) |
Peripheral vascular disease | 170 (27.6%) |
Preoperative medication use | |
Statin | 416 (67.6%) |
ACE inhibitor | 192 (31.2%) |
Baseline laboratory data | |
Creatinine, mg/dl | 1.01 (0.74, 1.60) |
eGFR, ml/min/1.73 m2 | 72.8 (38.5 96.7) |
Hematocrit, % | 34 (25, 43) |
Perioperative atorvastatin treatment assignment | 308 (50%) |
Procedure characteristics | |
CABG surgery | 301 (48.9%) |
Valve surgery | 397 (64.6%) |
Cardiopulmonary bypass use | 435 (70.7%) |
Cardiopulmonary bypass time, min | 110.0 (0, 211.6) |
Aortic cross clamp use | 291 (47.3%) |
Aortic cross clamp time, min | 0 (0, 139.6) |
Intraoperative fluids | |
Intravenous crystalloid, mL | 1600 (1000, 3000) |
Intravenous hydroxyethyl starch, mL | 0 (0, 0)a |
Urine output, mL | 430 (175, 946) |
Arterial lactate, maximum intraoperative, mmol/L | 1.7 (0.9, 3.8) |
Length of surgery, hours | 5.1 (3.6, 7.8) |